KA/EN
Register
Medicines reference
Search
Search
Product

Dekort

Favourites

Dexamethasone · Deva Holding

1 form: tablet. In force in Georgia: 1 of 1 (human register).

Forms and doses1 of 1 in force in Georgia

Form Dose Frequency Georgia
0.5 mg, Tablet No label dose in the reference yet - Georgia Yes, human
In force until 24 Feb 2031
Human (Ministry of Health, RAMA)
In the register: დეკორტი 0.5 მგ, აბი
№ რ-044863
Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration

Dekort 0.5 mg, Tablet

tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Systemic oral dexamethasone as short-term symptomatic or adjunct anti-inflammatory/immunosuppressive treatment for a diagnosed corticosteroid-responsive disease, with cause-directed care and monitoring
6.1/10
Situational / acceptable
vetman assessment

Dekort

0.5 mg, tablet, human medicine
Assessed clinical scopeDog · Systemic oral dexamethasone as short-term symptomatic or adjunct anti-inflammatory/immunosuppressive treatment for a diagnosed corticosteroid-responsive disease, with cause-directed care and monitoring · By mouth
Care settingVeterinarian-directed treatment, usually at home after diagnosis, with an exact weight-based dose, early reassessment, the shortest effective course and a planned taper when exposure is sustained
vetman score 6.1/10 Situational / acceptable
Evidence confidence: Low Georgia: Yes, human · № რ-044863 · Verified on 16 Oct 2026 Off-label use

A potent, evidence-supported oral glucocorticoid for selected short-term inflammatory or immune-mediated roles, but these exact human products remain off-label. Confirm the exact strength, use a measurable weight-based dose, treat the underlying cause, avoid preventable interactions and prefer a shorter-acting corticosteroid when prolonged adjustable therapy is required.

Regulatory and scientific credibility6.0/10

This exact human 0.5 mg tablet has a sourced current Georgian registration and an exact official manufacturer instruction. Exhaustive current checks record no exact EU/EEA, GB or US registration, and no regulator-hosted complete exact-product dossier was located; veterinary use is off-label.

Clinical efficacy7.5/10

Dexamethasone is a potent, well-absorbed, long-acting oral glucocorticoid, and a current authorised veterinary 0.5 mg product directly supports symptomatic or adjunct treatment of inflammatory and allergic disease in dogs. It can provide strong short-term control when the diagnosis and dose target are correct, but does not cure the underlying disease and is usually less suitable than a shorter-acting steroid for adjustable chronic therapy.

Safety and tolerability5.0/10

Short, appropriately selected courses can be manageable, but cortisol suppression is very common with the authorised veterinary comparator and long-acting dexamethasone can cause infection, gastrointestinal ulceration, metabolic effects, delayed healing and HPA-axis suppression. Long-term oral use is specifically discouraged when a shorter-acting alternative such as prednisolone can provide control.

Clinical practicality6.0/10

A 0.5 mg whole-tablet unit is compact and simple to store and can fit some small-to-medium canine doses, but this human tablet is not the flavoured, quarterable veterinary comparator. The exact instruction does not establish fractional veterinary dosing, so smaller increments or many-tablet regimens require a more suitable strength or validated compound.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use as a substitute for diagnosis or cause-directed treatment. Dexamethasone can suppress fever, pain and inflammation while infection, neoplasia, endocrine disease or another underlying disorder progresses.
  • Do not start immunosuppressive dexamethasone with an uncontrolled viral, fungal, bacterial or parasitic infection. Establish appropriate cause-directed control first or concurrently when steroid benefit is essential.
  • Avoid concurrent NSAIDs and use an indication-appropriate washout when switching; the combination materially increases gastrointestinal ulceration, perforation and bleeding risk. Avoid use with active gastrointestinal ulceration.
  • Avoid or use only after explicit benefit-risk assessment in diabetes mellitus, hyperadrenocorticism, uncontrolled hypertension, glaucoma, osteoporosis, important cardiac or renal dysfunction, corneal ulceration or major thrombotic risk.
  • Do not administer modified-live vaccines during immunosuppressive treatment. Review vaccination timing and expected immune response before and after systemic dexamethasone exposure.
  • Use only the exact prescribed strength and a dose that can be measured accurately. Do not split or crush an unscored tablet to improvise a small dose unless the exact product instruction and a validated preparation method support dose uniformity.
  • Use the lowest effective dose for the shortest effective period and reassess early. Dexamethasone is long acting; alternate-day dosing does not reliably allow HPA-axis recovery, and a shorter-acting corticosteroid is usually preferable for prolonged adjustable treatment.
  • After sustained supraphysiologic exposure, taper rather than stop abruptly. Monitor weight, appetite, water intake and urination, blood pressure, infection signs, CBC, chemistry, glucose and urine according to dose, duration and patient risk.
  • Review all concurrent medicines. Enzyme inducers may reduce exposure, potassium-depleting diuretics and cardiac glycosides increase electrolyte-related risk, insulin requirements may change and other immunosuppressants increase infection risk.
  • Safety of these exact human tablets in breeding, pregnant, lactating, neonatal or growing dogs and cats is not established. Dexamethasone can affect fetal development, parturition, growth and immune response; use only after a documented veterinary benefit-risk assessment.
Assessment sources
  1. Dekort 0.5 mg official instruction2026
  2. Dexacortone 0.5 mg veterinary SPC2025
  3. Dexacortone 0.5 mg UPD2026
  4. MSD corticosteroids2026
  5. AAHA allergic disease guideline2023
  6. Feline oral dexamethasone efficacy2021
  7. Feline dexamethasone diabetogenic study2009
  8. Canine glucocorticoid AEs2020
  9. RECOVER allergy/anaphylaxis2026
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Systemic oral dexamethasone as short-term symptomatic or adjunct anti-inflammatory/immunosuppressive treatment for a diagnosed corticosteroid-responsive disease, with cause-directed care and monitoring
6.2/10
Situational / acceptable
vetman assessment

Dekort

0.5 mg, tablet, human medicine
Assessed clinical scopeCat · Systemic oral dexamethasone as short-term symptomatic or adjunct anti-inflammatory/immunosuppressive treatment for a diagnosed corticosteroid-responsive disease, with cause-directed care and monitoring · By mouth
Care settingVeterinarian-directed treatment, usually at home after diagnosis, with an exact weight-based dose, early reassessment, the shortest effective course and a planned taper when exposure is sustained
vetman score 6.2/10 Situational / acceptable
Evidence confidence: Low Georgia: Yes, human · № რ-044863 · Verified on 16 Oct 2026 Off-label use

A potent, evidence-supported oral glucocorticoid for selected short-term inflammatory or immune-mediated roles, but these exact human products remain off-label. Confirm the exact strength, use a measurable weight-based dose, treat the underlying cause, avoid preventable interactions and prefer a shorter-acting corticosteroid when prolonged adjustable therapy is required.

Regulatory and scientific credibility6.0/10

This exact human 0.5 mg tablet has a sourced current Georgian registration and an exact official manufacturer instruction. Exhaustive current checks record no exact EU/EEA, GB or US registration, and no regulator-hosted complete exact-product dossier was located; veterinary use is off-label.

Clinical efficacy7.5/10

A current authorised veterinary 0.5 mg product directly supports oral dexamethasone for inflammatory and allergic disease in cats, and a small prospective feline study found oral absorption and improvement in hypersensitivity dermatitis. The evidence supports useful short-term control, not every possible immune-mediated claim; response is diagnosis-dependent and treatment must remain adjunctive to cause control.

Safety and tolerability4.5/10

The authorised veterinary label documents very common cortisol suppression and broad glucocorticoid toxicity. In cats, controlled pilot data suggest greater diabetogenic effects than equipotent prednisolone, while prolonged immunosuppressive exposure can produce hyperglycaemia, infection, hepatopathy, skin/muscle change, gastrointestinal injury and adrenal suppression; this narrows the margin for chronic use.

Clinical practicality7.0/10

A 0.5 mg whole-tablet unit often fits clinically relevant feline dosing better than higher human strengths and is simple to store. It is nevertheless an unflavoured human tablet without the veterinary comparator’s validated quarter divisions; cats needing smaller increments, reluctant pill-takers and multi-step tapers may require a more suitable veterinary or compounded form.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use as a substitute for diagnosis or cause-directed treatment. Dexamethasone can suppress fever, pain and inflammation while infection, neoplasia, endocrine disease or another underlying disorder progresses.
  • Do not start immunosuppressive dexamethasone with an uncontrolled viral, fungal, bacterial or parasitic infection. Establish appropriate cause-directed control first or concurrently when steroid benefit is essential.
  • Avoid concurrent NSAIDs and use an indication-appropriate washout when switching; the combination materially increases gastrointestinal ulceration, perforation and bleeding risk. Avoid use with active gastrointestinal ulceration.
  • Avoid or use only after explicit benefit-risk assessment in diabetes mellitus, hyperadrenocorticism, uncontrolled hypertension, glaucoma, osteoporosis, important cardiac or renal dysfunction, corneal ulceration or major thrombotic risk.
  • Do not administer modified-live vaccines during immunosuppressive treatment. Review vaccination timing and expected immune response before and after systemic dexamethasone exposure.
  • Use only the exact prescribed strength and a dose that can be measured accurately. Do not split or crush an unscored tablet to improvise a small dose unless the exact product instruction and a validated preparation method support dose uniformity.
  • Use the lowest effective dose for the shortest effective period and reassess early. Dexamethasone is long acting; alternate-day dosing does not reliably allow HPA-axis recovery, and a shorter-acting corticosteroid is usually preferable for prolonged adjustable treatment.
  • After sustained supraphysiologic exposure, taper rather than stop abruptly. Monitor weight, appetite, water intake and urination, blood pressure, infection signs, CBC, chemistry, glucose and urine according to dose, duration and patient risk.
  • Review all concurrent medicines. Enzyme inducers may reduce exposure, potassium-depleting diuretics and cardiac glycosides increase electrolyte-related risk, insulin requirements may change and other immunosuppressants increase infection risk.
  • Safety of these exact human tablets in breeding, pregnant, lactating, neonatal or growing dogs and cats is not established. Dexamethasone can affect fetal development, parturition, growth and immune response; use only after a documented veterinary benefit-risk assessment.
Assessment sources
  1. Dekort 0.5 mg official instruction2026
  2. Dexacortone 0.5 mg veterinary SPC2025
  3. Dexacortone 0.5 mg UPD2026
  4. MSD corticosteroids2026
  5. AAHA allergic disease guideline2023
  6. Feline oral dexamethasone efficacy2021
  7. Feline dexamethasone diabetogenic study2009
  8. Canine glucocorticoid AEs2020
  9. RECOVER allergy/anaphylaxis2026
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Dexamethasone0.5 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Deva Holding · Türkiye
Registration
Georgia Yes, human
In force until 24 Feb 2031
Human (Ministry of Health, RAMA)
In the register: დეკორტი 0.5 მგ, აბი
№ რ-044863
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Active substance doses, with sources

Each dose comes with its source. Check the label of the product you use.

Active substance Dexamethasone
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
0.05–0.2 mg/kg Dog Inflammation By mouth once daily in the morning
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Dexacortone 0.5 mg and 2.0 mg Chewable Tablets for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
0.1 mg/kg Dog, Cat Allergic Reaction Intramuscular as needed
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Dexadreson 2 mg/ml Solution for Injection - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
0.05–0.2 mg/kg Cat Inflammation By mouth once daily in the evening
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Dexacortone 0.5 mg and 2.0 mg Chewable Tablets for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025

Known Contraindications

  • Critical
    Do not use corticosteroids, topically or systemically, while a corneal ulcer is present. They slow healing of the corneal epithelium and can increase collagenase activity, which may turn the ulcer into a melting ulcer.
    Sources: MSD Vet Manual
  • Critical
    Do not use dexamethasone in animals with diabetes mellitus or hyperadrenocorticism unless specifically required and closely monitored.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in animals with diabetes mellitus or hyperadrenocorticism.
    Sources: VMD SPC · VMD
  • Critical
    Do not use dexamethasone in animals with osteoporosis because corticosteroids increase protein catabolism and can reduce bone mass.
    Sources: VMD SPC · VMD
  • Critical
    Do not use dexamethasone in animals with cardiac or renal dysfunction, including congestive heart failure, unless specifically required and closely monitored.
    Sources: VMD SPC · VMD
  • Critical
    the product should not be used in animals suffering from diabetes, chronic nephritis, renal disease, congestive heart failure, osteoporosis and in viral infections during the viraemic stage
    Sources: VMD SPC · VMD
  • Critical
    Do not use in animals with cardiac or renal dysfunction.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in animals with gastro-intestinal ulceration.
    Sources: VMD SPC · VMD
  • Critical
    Do not use dexamethasone in animals with glaucoma.
    Sources: VMD SPC · VMD
  • Critical
    Do not use systemic dexamethasone in animals with burns unless specifically indicated and closely monitored.
    Sources: VMD SPC · VMD
  • Critical
    Do not use dexamethasone during pregnancy because early exposure can cause fetal abnormalities and late exposure can induce abortion or premature parturition.
    Sources: VMD SPC · VMD
  • Critical
    Known hypersensitivity to dexamethasone, another corticosteroid, or any excipient is a contraindication.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in animals with viral or mycotic infections.
    Sources: VMD SPC · VMD
  • Warning
    Use with particular caution in an immunocompromised patient because corticosteroids delay wound healing and can exacerbate an existing infection.
    Sources: VMD SPC · VMD
  • Warning
    Corticoids such as dexamethasone should be used with caution in patients with hypertension.
    Sources: VMD SPC · VMD
  • Warning
    Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age) should be based on a benefit/risk assessment by the attending veterinarian.
    Sources: VMD SPC · VMD
  • Warning
    Do not use concomitantly with attenuated alive vaccine dexamethasone should not be used in combination with vaccines or within two weeks after vaccination
    Sources: VMD SPC · VMD
  • Caution
    Due to the long duration of effect of dexamethasone alternate day therapy is not an adequate way to allow the hypothalamic-pituitary-adrenal axis to recover.
    Sources: VMD SPC · VMD
  • Caution
    Use cautiously in geriatric or debilitated animals because corticosteroids increase protein catabolism. Prolonged treatment can cause cushingoid changes, including fat redistribution, muscle weakness and atrophy, and osteoporosis.
    Sources: VMD SPC · VMD

Known Drug Interactions

  • Contraindicated Robenacoxib + Dexamethasone
    Do not give robenacoxib together with other non-steroidal anti-inflammatory drugs or glucocorticoids because adverse gastrointestinal and renal effects may increase.
    Recommendation: Do not use these drugs together. Allow a treatment-free interval of at least 24 hours after the previous anti-inflammatory drug, extending it when required by that drug’s pharmacokinetics.
  • Major warning Meloxicam + Dexamethasone
    The concomitant use of this veterinary medicinal product with non-steroidal anti-inflammatory drugs may exacerbate gastrointestinal tract ulceration.
    Recommendation: Avoid concurrent administration. Observe an appropriate washout period when switching. If both are essential, provide gastroprotection and monitor gastrointestinal signs closely.
    Sources: VMD SPC · VMD
  • Major warning Carprofen + Dexamethasone
    Do not give other non-steroidal anti-inflammatory drugs or glucocorticoids concurrently with carprofen or within 24 hours of treatment because gastrointestinal ulceration or perforation may occur.
    Recommendation: Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.
    Sources: FDA
  • Major warning Dexamethasone + Insulin glargine
    Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.
    Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.
    Sources: FDA · AAHA
  • Major warning Dexamethasone + Insulin human
    Glucocorticoids, progestogens, and certain endocrinopathies can have an antagonistic effect on insulin activity. Glucocorticoid and progestogen use should be avoided.
    Recommendation: Avoid the combination. If the glucocorticoid cannot be discontinued within 2 weeks, the insulin dose may need to be increased; monitor glycaemia.
    Sources: FDA · AAHA
  • Minor warning Furosemide + Dexamethasone
    The risk of hypokalaemia may be increased if dexamethasone is administered together with potassium depleting diuretics.
    Recommendation: Monitor serum potassium. Hypokalaemia also increases cardiac glycoside toxicity.
    Sources: VMD SPC · VMD
  • Minor warning Dexamethasone + Torasemide
    The risk of hypokalaemia may be increased if dexamethasone is administered together with potassium depleting diuretics.
    Recommendation: Monitor serum potassium.
    Sources: VMD SPC · VMD

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (31 more) Hide additional products

Same active ingredients 9

Same therapeutic group 22

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗